Format

Send to

Choose Destination
JAMA Intern Med. 2016 Sep 1;176(9):1391-3. doi: 10.1001/jamainternmed.2016.3411.

Generic Drug Approvals Since the 1984 Hatch-Waxman Act.

Author information

1
Yale University School of Medicine, New Haven, Connecticut.
2
Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
3
Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts4Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut.
4
Departments of Medicine and the History of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
5
Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut6Section of General Internal Medicine and the Robert Wood Johnson Foundation Clinical Scholars Program, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut7Department of Health Policy and Management, Yale University School of Public Health, New Haven, Connecticut.

Comment in

PMID:
27428055
DOI:
10.1001/jamainternmed.2016.3411
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center